Open AccessMultinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of severe dermatological toxicities from checkpoint inhibitors
Author(s) -
Jennifer N. Choi,
Robin L. Anderson,
Ada G. Blidner,
Tim Cooksley,
Michael Dougan,
Ilya Glezerman,
Pamela Ginex,
Monica Girotra,
Dhiraj Gupta,
Douglas B. Johnson,
Vickie R. Shan,
María E. Suärez-Almazor,
Bernardo Leon Rapoport,
Mario E. Lacouture
Publication year - 2020
Publication title -
supportive care in cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.133
H-Index - 112
eISSN - 1433-7339
pISSN - 0941-4355
DOI - 10.1007/s00520-020-05706-4
Subject(s) - medicine , discontinuation , adverse effect , intensive care medicine , cancer , clinical trial , corticosteroid , refractory (planetary science) , randomized controlled trial , oncology , astrobiology , physics
Immune checkpoint inhibitors (ICIs) frequently result in cutaneous immune-related adverse events (IrAEs). Although the majority of these events are mild-to-moderate in severity, up to 5% are severe, which may lead to morbidity and dose interruption or discontinuation of ICI therapy. In addition, up to 25% of dermatologic IrAEs are corticosteroid-refractory or corticosteroid-dependent. These 2020 MASCC recommendations cover the diagnosis and management of cutaneous IrAEs with a focus on moderate-to-severe and corticosteroid-resistant events. Although the usage of immune-suppressive therapy has been advocated in this setting, there is a lack of randomized clinical trial data to provide a compelling level of evidence of its therapeutic benefit.